Cis-diamminedichloroplatinum (II) (Cis-DDP) is a relatively new chemotherapeutic agent used in the treatment of human neoplasms. This agent has proven to be especially effective in the treatment of testicular carcinoma. The main toxicities encountered with the use of Cis-DDP are nephrotoxicity, hematopoietic toxicity and ototoxicity. The nephrotoxicity is the most serious and it is the main dose limiting factor. The purpose of the present study was to monitor parameters used for assessing toxicities and to determine the urinary excretion halflife of platinum following the administration of Cis-DDP. The purpose was also to determine, if possible, what effect prehydration and mannitol diuresis had on these values as compared to previous studi...
Cisplatin (CDDP) is an anticancer drug. The clinical limitations associated with CDDP have stimulate...
Methodological tools for studies of the cytostatic agen cisplatin (CDDP) were explored and applied t...
The feasibility of monitoring cisplatin chemotherapy by measuring plati num (Pt) concentrations in b...
Platinum (Pt) based antineoplastics are important in cancer therapy. To date the Pt which is urinary...
The pharmacokinetics of total platinum (Pt) in plasma and cisplatin (CDDP)-DNA adducts in different ...
The antitumoral agent cis-diamminedichloroplatinum (II) was administered at doses of 40 mg m-2 body ...
Body distribution and retention of cis-dichlo rodiammine platinum, including liver uptake, were meas...
Cis-platinum or cis-diammine-dichloro-platinum (CDDP), a compound of platinum, has antineoplastic ac...
The pharmacokinetics of cisplatin were investigated in 14 patients, aged 10 months through 13 years ...
Total and ultrafilterable platinum (Pt) disposition was investigated during 49 courses of chemothera...
Preclinical studies were performed in mice, rats and dogs of cis-diamminedichloroplatinum(II) (CDDP)...
The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function o...
International audienceOvarian cancer is the leading cause of gynecological cancer-related death in W...
Patients cured of metastatic testicular cancer with cisplatin chemotherapy may suffer late adverse e...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pesso...
Cisplatin (CDDP) is an anticancer drug. The clinical limitations associated with CDDP have stimulate...
Methodological tools for studies of the cytostatic agen cisplatin (CDDP) were explored and applied t...
The feasibility of monitoring cisplatin chemotherapy by measuring plati num (Pt) concentrations in b...
Platinum (Pt) based antineoplastics are important in cancer therapy. To date the Pt which is urinary...
The pharmacokinetics of total platinum (Pt) in plasma and cisplatin (CDDP)-DNA adducts in different ...
The antitumoral agent cis-diamminedichloroplatinum (II) was administered at doses of 40 mg m-2 body ...
Body distribution and retention of cis-dichlo rodiammine platinum, including liver uptake, were meas...
Cis-platinum or cis-diammine-dichloro-platinum (CDDP), a compound of platinum, has antineoplastic ac...
The pharmacokinetics of cisplatin were investigated in 14 patients, aged 10 months through 13 years ...
Total and ultrafilterable platinum (Pt) disposition was investigated during 49 courses of chemothera...
Preclinical studies were performed in mice, rats and dogs of cis-diamminedichloroplatinum(II) (CDDP)...
The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function o...
International audienceOvarian cancer is the leading cause of gynecological cancer-related death in W...
Patients cured of metastatic testicular cancer with cisplatin chemotherapy may suffer late adverse e...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pesso...
Cisplatin (CDDP) is an anticancer drug. The clinical limitations associated with CDDP have stimulate...
Methodological tools for studies of the cytostatic agen cisplatin (CDDP) were explored and applied t...
The feasibility of monitoring cisplatin chemotherapy by measuring plati num (Pt) concentrations in b...